Ann LaCasce's professional career is devoted to the diagnosis and treatment of lymphoma. Her clinical effort is 60%, and she spends four half days a week in the clinic and six weeks on the inpatient hematologic malignancy service. Through her work with the NCCN, Alliance and Lymphoma Research Foundation, she is recognized as an expert both nationally and internationally, and has more than 12 years of experience in caring for complex patients with lymphoproliferative disorders. She was recently appointed to the National Cancer Institute Lymphoma Steering Committee. Her referral base is wide, including New England and locations throughout the United States. Ann is a member of the NCCN non-Hodgkin lymphoma panel, who establish guidelines for the diagnosis, evaluation and treatment of non-Hodgkin lymphoma, incorporating emerging data in real time. The guidelines and accompanying compendium of drugs and combinations are used by oncology practices nationally and determine reimbursement by many payers. Ann has been selected by the American Society of Hematology to lecture on lymphoma, speaking at the Highlights of ASH Symposium in the US and South America, 2014 State of the Art Symposia, and she served as co-chair and speaker for their new course on consultative malignant hematology. She was selected to serve as the lead author for the Hodgkin Lymphoma chapter in their Self-Assessment Program and recently authored a piece on Burkitt lymphoma for Blood’s “How I Treat” series. Ann serve as a consultant for the American Society of Hematology’s “consult a colleague” program. In addition, she contributes chapters on lymphoma in leading textbooks and journals, and is an author on several UpToDate topics in lymphoma, both non-Hodgkin’s and Hodgkin lymphoma.
As the Dana Farber Cancer Institute member of the Alliance Lymphoma Committee, Ann designs and conducts multi-center clinical trials in both Hodgkin and non-Hodgkin lymphomas. Her clinical research focuses on the study of novel drugs and combinations in lymphoma, and she is the principal investigator for an Alliance study examining PET adapted therapy in Hodgkin lymphoma. As a recent new member of the Lymphoma Research Foundation Scientific Advisory Board member, she selects recipients of career development awards and grants. Through this organization, she educates patients and families, is a frequent speaker at local venues, as the co-director of their national symposium in 2013, and co-chair of a new subcommittee on lymphoma adolescent and young adult population.
Education is Ann's other career focus. After joining the faculty at DFCI, she served as the hematologic malignancies educational coordinator for the hematology/oncology fellowship and was awarded the DFCI Medical Oncology Education Award in 2006. She led the development and directs the Advanced Fellowship in the Hematologic Malignancies. In 2011, she won the search for the DF/PCC Hematology/Oncology Fellowship Program Director. Over the past 3 years, Ann has worked to strengthen the clinical training and career mentorship they provide to fellows in hematology/oncology. On a local level, Ann serves on the BWH and Partners’ Education Committees. On the national level, she serves on the American Society of Hematology Committee on Training Programs, and she has developed fellowship specific curricular milestones in anticipation of the new reporting structure of the ACGME. Ann has selected award recipients of ASH grants for medical students, residents and fellows. At the medical residency level, she is active in education, leading case based discussions at morning report and lecturing on the topic of lymphoma. In terms of peer education, she lectures on lymphoma for CME courses both locally and nationally.Back to speakers